Skip to content

Pasadena Star News

50°F
Wednesday, January 7th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aditxt, Inc. - Common Stock (NQ:ADTX)

0.8778 -0.0047 (-0.53%)
Streaming Delayed Price Updated: 9:46 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aditxt, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
Via AB Newswire
Topics Artificial Intelligence
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Outlines bitXbio Strategy and Proposes Corporate Name Change
Via Investor Brand Network
News headline image
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective Nov. 3, 2025
Via Investor Brand Network
News headline image
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Begins Enrollment in Clinical Study for Blood-Based Endometriosis Test
Via Investor Brand Network
News headline image
Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market
From Aditxt, Inc.
Via Business Wire
News headline image
Kartoon Studios (NYSE American: TOON) Expands Global Reach as Leading Force in Family Entertainment and Animated Media
Via AB Newswire
Topics Intellectual Property
News headline image
Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Portfolio Company CEO Honored at 2025 STIMULATE Conference
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
Via Investor Brand Network
Topics Initial Public Offering
News headline image
Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
Via Investor Brand Network
News headline image
Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
Via Investor Brand Network
News headline image
Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
Via Investor Brand Network
News headline image
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
News headline image
Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
From Aditxt, Inc.
Via Business Wire
News headline image
Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
Via Investor Brand Network
News headline image
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
Via Investor Brand Network
News headline image
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
From Aditxt, Inc.
Via Business Wire
News headline image
KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
Via Business Wire
News headline image
KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.